Conclusion Since the closure of the GROINNS-2 trial we have continued with sentinel lymph node identification for women with clinical early stage vulval cancer. We have shown high level of adherence to the GROINNS trial protocol. There were a few patients managed as day-case which was of benefit to the patients.

2022-RA-1069-ESGO  
VULVAR BASAL CELL CARCINOMA – 5 YEARS EXPERIENCE FROM TERTIARY CARE CENTRE AND A CASE REPORT OF UNUSUAL RECURRENCE OF VULVAR BASAL CELL CARCINOMA IN PARAORTIC LYMPH NODES

Vid Jansa, Branko Čvjetičanin, Spela Smrkolj, Luka Kovac, Mateja Lasic, Neza Lebic Belcijan, Leon Meglic, Borut Kobal. Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Ljubljana, Slovenia

10.1136/ijgc-2022-ESGO.945

Introduction/Background Vulvar basal cell carcinoma is rare vulvar neoplasm accounting for less than 5% of all vulvar neoplasms. Vulvar basal cell carcinoma is usually an indolent and destructive tumor that rarely metastasizes.

Methodology We retrospectively analyse clinical features and management of patients diagnosed with rare vulvar tumor – basal cell carcinoma (BCC) at the University Medical Centre Ljubljana in the last 5 years. A total of 10 patients were identified.

Results Mean age at diagnosis was 75.6 years. All of the patients were Caucasians. All of the patients presented with vulvar lump. Majority of tumors were histologically defined as nodular type or superficial type. All patients were managed surgically with wide local excision. We observed two recurrences in our case series. In one recurrence was local and the patient was treated with wide local re-excision. In the second patient recurrence was observed with unusual location in paraortic lymph nodes.

Conclusion According to literature review this is the first case of recurrence of vulvar basal cell carcinoma in paraaortic lymph nodes. Basal cell carcinoma tends to grow locally in a destructive pattern and metastatic spread is rare.

2022-RA-1078-ESGO  
SERVICE EVALUATION OF WOMEN WITH STAGE 1B VULVAL CANCER WHO UNDERWENT GROIN SENTINEL LYMPH NODE BIOPSY: THE SOUTH EAST WALES GYNAECOLOGICAL ONCOLOGY CENTRE (SEWGOC) EXPERIENCE

Hassan Zeinah, Monica Tyczynska, Sadie Jones, Ewelina Rzyska, Kenneth Lim, Robert Howells, Aarti Sharma. The South East Wales Gynaecological Oncology Centre, Cardiff, UK

10.1136/ijgc-2022-ESGO.946

Introduction/Background The current standard of care for vulval cancer patients with pre-operative stage 1b involves removal of the lesion and assessment of the groin nodes by either performing groins sentinel lymph node biopsy (SLNB) where possible or full groin nodes dissection (GND). For SLNB to be performed, the preoperative cancer stage should be ideally 1B, macroscopic vulval lesion ≤ 4cm/single lesion, not involving any midline structures. The aim of this project is to evaluate the outcomes in women with stage 1b vulval cancer who SLNB as part of their vulval cancer treatment.

Methodology Retrospective review of electronic medical records for all women who underwent SLNB from 1st January 2018 to 31st December 2021 at the South East Wales Gynaecological Oncology Centre (SEWGOC)

Results Thirty-two patients were identified in this time period with stage 1b vulval cancer (as per preoperative biopsy and/or imaging) and were planned to have SLNB. Thirty-one patients underwent successful SLNB. Nine patients (Twenty nine percent) of those who underwent SLNB were found to have metastasis within sentinel lymph node and therefore were upstaged to stage III postoperatively. Those patients were then managed with either full groin node dissection, radiotherapy or both. None of the patients with negative sentinel lymph nodes had a recurrence in the inguinal lymph nodes during the follow up period.

Conclusion Approximately 30% of our preoperative stage 1b vulval cancer were upstaged to stage 3 due to metastatic disease in the SLNB. This service evaluation shows that SLNB is effective method in treatment of early stage vulval cancer. We were able to avoid full groin node dissection with its associated morbidity in almost 70% of our patients and also identify women who were not stage 1b and needed further treatment in the form of further GND with or without radiotherapy.

2022-RA-1086-ESGO  
SEBACEOUS CARCINOMA (SC) OF THE VULVA – A CASE REPORT AND LITERATURE REVIEW

1Hassan Zeinah, 1Gemma Owen, 1Sadie Jones, 1Kenneth Lim, 1Robert Howells, 1Adam Boyde, 1Ewelina Rzyska, 1Aarti Sharma. 1The South East Wales Gynaecological Oncology Centre, Cardiff, UK; 1Department of Pathology, University Hospital of Wales, Cardiff, UK

10.1136/ijgc-2022-ESGO.947